Vident Advisory LLC Acquires 36,850 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Vident Advisory LLC boosted its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 31.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 155,874 shares of the biotechnology company's stock after acquiring an additional 36,850 shares during the period. Vident Advisory LLC owned 0.05% of Exelixis worth $5,191,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in EXEL. Invesco Ltd. raised its stake in Exelixis by 308.1% in the 4th quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company's stock valued at $132,376,000 after acquiring an additional 3,001,204 shares during the period. Norges Bank bought a new stake in Exelixis in the 4th quarter valued at $94,867,000. Caisse DE Depot ET Placement DU Quebec raised its stake in Exelixis by 330.4% in the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 2,484,395 shares of the biotechnology company's stock valued at $82,730,000 after acquiring an additional 1,907,167 shares during the period. Arrowstreet Capital Limited Partnership grew its holdings in Exelixis by 104.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 3,159,395 shares of the biotechnology company's stock valued at $105,208,000 after buying an additional 1,613,482 shares in the last quarter. Finally, AQR Capital Management LLC grew its holdings in Exelixis by 25.7% in the 4th quarter. AQR Capital Management LLC now owns 3,967,005 shares of the biotechnology company's stock valued at $132,101,000 after buying an additional 810,857 shares in the last quarter. Institutional investors own 85.27% of the company's stock.

Insider Transactions at Exelixis

In related news, Director Stelios Papadopoulos sold 36,508 shares of the firm's stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $44.35, for a total transaction of $1,619,129.80. Following the completion of the sale, the director now owns 1,279,416 shares of the company's stock, valued at $56,742,099.60. This trade represents a 2.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Christopher J. Senner sold 29,314 shares of the firm's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $36.14, for a total value of $1,059,407.96. Following the sale, the chief financial officer now directly owns 779,607 shares of the company's stock, valued at $28,174,996.98. This represents a 3.62% decrease in their position. The disclosure for this sale can be found here. Insiders sold 520,942 shares of company stock worth $22,930,002 over the last ninety days. 2.82% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages have commented on EXEL. StockNews.com lowered Exelixis from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 15th. Stephens reaffirmed an "equal weight" rating and issued a $29.00 price objective on shares of Exelixis in a report on Wednesday, February 12th. Barclays upped their price objective on Exelixis from $25.00 to $29.00 and gave the company an "equal weight" rating in a report on Thursday, February 13th. Wells Fargo & Company reaffirmed a "market outperform" rating on shares of Exelixis in a report on Thursday, April 17th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price objective on shares of Exelixis in a report on Thursday, March 27th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $38.94.

Exelixis Trading Down 1.6%

Exelixis stock opened at $44.69 on Tuesday. The company has a market capitalization of $12.19 billion, a PE ratio of 25.25, a P/E/G ratio of 1.13 and a beta of 0.25. Exelixis, Inc. has a 12 month low of $20.14 and a 12 month high of $48.85. The stock has a 50-day moving average price of $37.38 and a two-hundred day moving average price of $35.91.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.